Factors associated with the number of drugs in darunavir/cobicistat regimens
| Autor: | Martinez, E, Negredo, E, Knobel, H, Ocampo, A, Sanz, J, Garcia-Fraile, L, Martin-Carbonero, L, Lozano, F, Gonzalez-Domenech, CM, Gutierrez, M, Montero, M, Boix, V, Payeras, A, Torralba, M, Gonzalez-Cordon, A, Moreno, A, Alejos, B, Perez-Elias, MJ, GeSIDA 9316 CODAR Study Grp |
|---|---|
| Rok vydání: | 2020 |
| Zdroj: | JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante instname Journal of Antimicrobial Chemotherapy r-IGTP: Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol Institut de Recerca Germans Trias i Pujol (IGTP) |
| ISSN: | 0305-7453 |
| Popis: | Background: Darunavir/cobicistat can be used as mono, dual, triple or more than triple therapy. Objectives: To assess factors associated with the number of drugs in darunavir/cobicistat regimens. Methods: A nationwide retrospective cohort study of consecutive HIV-infected patients initiating darunavir/cobicistat in Spain from July 2015 to May 2017. Baseline characteristics, efficacy and safety at 48 weeks were compared according to the number of drugs used. Results: There were 761 patients (75% men, 98% were antiretroviral-experienced, 32% had prior AIDS, 84% had HIV RNA = 200 CD4 cells/mm(3)) who initiated darunavir/cobicistat as mono (n=308, 40%), dual (n=173, 23%), triple (n=253, 33%) or four-drug (n=27, 4%) therapy. Relative to monotherapy, triple therapy was more common in men aged |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|